AI assistant
Sending…
KALA BIO, Inc. — Director's Dealing 2021
Mar 3, 2021
35091_dirs_2021-03-03_eb4e0b70-d086-4cb7-a250-8c39e6129e7d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2021-03-01
Reporting Person: Chen Hongming (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-01 | Common Stock | M | 9500 | $2.3 | Acquired | 243015 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-03-01 | Stock Option (right to buy | $2.3 | M | 9500 | Disposed | 2024-10-02 | Common Stock (9500) | Direct |
Footnotes
F1: Includes 99,666 unvested RSUs.
F2: The option was fully vested.
More from KALA BIO, Inc.
Interim / Quarterly Report
2026
May 15
Annual Report
2026
Apr 15
Regulatory Filings
2026
Mar 17
Regulatory Filings
2026
Mar 17
Capital/Financing Update
2026
Mar 4
Board/Management Information
2026
Feb 20
Major Shareholding Notification
2026
Feb 17
Capital/Financing Update
2026
Feb 9
Director's Dealing
2026
Feb 9
Director's Dealing
2026
Feb 9